Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Ocular Therapeutix, Inc. (OCUL) had Revenue of $10.79M for the most recently reported fiscal quarter, ending 2026-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	$10.79M
Net Income	$-88.61M
Cost of Goods Sold	$1.33M
Gross Profit	$9.46M
Operating Expenses	$104.12M
Operating Income	$-93.34M
Non-Operating Income/Expense	$4.73M
Pre-Tax Income	$-88.61M
Normalized Pre-Tax Income	$-88.61M
Income after Taxes	$-88.61M
Income from Continuous Operations	$-88.61M
Consolidated Net Income/Loss	$-88.61M
Normalized Income after Taxes	$-88.61M
EBIT	$-93.34M
EBITDA	$-92.06M
Weighted-Average Shares Outstanding (Basic)	224.10M
Weighted-Average Shares Outstanding (Diluted)	224.10M
Earnings per Share (EPS) (Basic)	$-0.40
Earnings per Share (EPS) (Diluted)	$-0.40
Balance Sheet Financials
Current Assets	$706.00M
Property, Plant, and Equipment	$18.43M
Long-Term Assets	$26.53M
Total Assets	$732.53M
Current Liabilities	$47.68M
Long-Term Debt	$72.06M
Long-Term Liabilities	$103.27M
Total Liabilities	$150.96M
Common Equity	$581.57M
Tangible Shareholders Equity	$581.57M
Shareholders Equity	$581.57M
Common Shares Outstanding	218.90M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-65.99M
Cash Flow from Investing Activities	$-4.66M
Cash Flow from Financial Activities	$0.29M
Beginning Cash	$738.67M
End Cash	$668.31M
Increase/Decrease in Cash	$-70.36M
Stock-Based Compensation	$15.58M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	14.81
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.11
Debt to Equity Ratio	0.12
Gross Margin	87.68%
Operating Margin	-865.46%
EBIT Margin	-865.46%
EBITDA Margin	--
Pre-Tax Profit Margin	-821.62%
Profit Margin	-821.62%
Free Cash Flow	$-70.66M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.01
Inventory Turnover	0.36
Receiveable Turnover	0.44
Days Sales in Receivables	203.17
Return on Equity	-15.24%
Return on Tangible Equity	-15.24%
Return on Assets	-12.10%
Return on Investments	-13.56%
Book Value Per Share	$2.66
Free Cash Flow per Share	$-0.32
Operating Cash Flow per Share	$-0.29

Data from Zacks Investment Research, Inc.